Treatment of car t-cell toxicity
AssigneesAdc Therapeutics SA, MedImmune, LLC
InventorTomasz Sablinski
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for improving the safety profile of adoptive cell transfer therapies. In particular, the present disclosure relates to methods for improving the safety profile of CAR T-cell therapies. Disclosed is an anti-CD25 antibody-drug-conjugate for use in a method of treatment or prevention of CAR immune cell toxicity in an individual.
Claims21
-28. (canceled)
A method for treating or preventing CAR immune cell toxicity in an individual, the method comprising administering to the individual an effective amount of an anti-CD25 antibody drug conjugate (ADC).
The method according to claim 46, wherein the CAR T-cell is a 1st generation CAR T-cell, a 2nd generation CAR T-cell, a 3rd generation CAR T-cell, a 4th generation CAR T-cell, a TRUCK, a smart CAR, or an iCAR.
Dependencies are inferred from the claim text.